Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229011327> ?p ?o ?g. }
- W4229011327 endingPage "654" @default.
- W4229011327 startingPage "643" @default.
- W4229011327 abstract "Cancer stem cells (CSCs) virtually present in all tumors albeit in small numbers are primarily responsible for driving cancer progression, metastasis, drug resistance, and recurrence. Prostate cancer (PCa) is the second most frequent cancer in men worldwide, and castration resistant prostate cancer (CRPC) remains a major challenge despite the tremendous advancements in medicine. Currently, none of the available treatment options are effective in treating CRPC. We earlier reported that VNPP433-3β, the lead next-generation galeterone analog is effective in treating preclinical in vivo models of CRPC. In this study using RNA-seq, cytological, and biochemical methods, we report that VNPP433-3β inhibits prostate CSCs by targeting key pathways critical to stemness and epithelial–mesenchymal transition. VNPP433-3β inhibits CSCs in PCa, presumably by degrading the androgen receptor (AR) thereby decreasing the AR-mediated transcription of several stem cell markers including BMI1 and KLF4. Transcriptome analyses by RNA-seq, Ingenuity Pathway Analysis, and Gene Set Enrichment Analysis demonstrate that VNPP433-3β inhibits transcription of several genes and functional pathways critical to the prostate CSCs thereby inhibiting CSCs in PCa besides targeting the bulk of the tumor." @default.
- W4229011327 created "2022-05-08" @default.
- W4229011327 creator A5000223629 @default.
- W4229011327 creator A5008874540 @default.
- W4229011327 creator A5010668315 @default.
- W4229011327 creator A5013588870 @default.
- W4229011327 creator A5025943203 @default.
- W4229011327 creator A5027230455 @default.
- W4229011327 creator A5033818354 @default.
- W4229011327 creator A5044862124 @default.
- W4229011327 creator A5069095946 @default.
- W4229011327 date "2022-05-05" @default.
- W4229011327 modified "2023-10-16" @default.
- W4229011327 title "Transcriptome profiling reveals that VNPP433‐3β, the lead next‐generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial–mesenchymal transition and stem cell markers" @default.
- W4229011327 cites W1521243242 @default.
- W4229011327 cites W1573780709 @default.
- W4229011327 cites W1775309324 @default.
- W4229011327 cites W1801117552 @default.
- W4229011327 cites W1897724420 @default.
- W4229011327 cites W1965458767 @default.
- W4229011327 cites W1979945039 @default.
- W4229011327 cites W1985339653 @default.
- W4229011327 cites W1988976106 @default.
- W4229011327 cites W1989802325 @default.
- W4229011327 cites W1997930286 @default.
- W4229011327 cites W2014691022 @default.
- W4229011327 cites W2021515035 @default.
- W4229011327 cites W2023300506 @default.
- W4229011327 cites W2030702612 @default.
- W4229011327 cites W2059705857 @default.
- W4229011327 cites W2082848009 @default.
- W4229011327 cites W2114817620 @default.
- W4229011327 cites W2123873958 @default.
- W4229011327 cites W2130410032 @default.
- W4229011327 cites W2153597782 @default.
- W4229011327 cites W2160689782 @default.
- W4229011327 cites W2181283187 @default.
- W4229011327 cites W2306322539 @default.
- W4229011327 cites W2336773997 @default.
- W4229011327 cites W2531281086 @default.
- W4229011327 cites W2534223538 @default.
- W4229011327 cites W2623594410 @default.
- W4229011327 cites W2763367287 @default.
- W4229011327 cites W2787308302 @default.
- W4229011327 cites W2799624200 @default.
- W4229011327 cites W2800947413 @default.
- W4229011327 cites W2883731008 @default.
- W4229011327 cites W2888022095 @default.
- W4229011327 cites W2891597765 @default.
- W4229011327 cites W2895950224 @default.
- W4229011327 cites W2923110687 @default.
- W4229011327 cites W2971040096 @default.
- W4229011327 cites W2981759193 @default.
- W4229011327 cites W2999417355 @default.
- W4229011327 cites W3047693299 @default.
- W4229011327 cites W3094518505 @default.
- W4229011327 cites W4200053046 @default.
- W4229011327 cites W4229011327 @default.
- W4229011327 cites W746610600 @default.
- W4229011327 doi "https://doi.org/10.1002/mc.23406" @default.
- W4229011327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35512605" @default.
- W4229011327 hasPublicationYear "2022" @default.
- W4229011327 type Work @default.
- W4229011327 citedByCount "21" @default.
- W4229011327 countsByYear W42290113272022 @default.
- W4229011327 countsByYear W42290113272023 @default.
- W4229011327 crossrefType "journal-article" @default.
- W4229011327 hasAuthorship W4229011327A5000223629 @default.
- W4229011327 hasAuthorship W4229011327A5008874540 @default.
- W4229011327 hasAuthorship W4229011327A5010668315 @default.
- W4229011327 hasAuthorship W4229011327A5013588870 @default.
- W4229011327 hasAuthorship W4229011327A5025943203 @default.
- W4229011327 hasAuthorship W4229011327A5027230455 @default.
- W4229011327 hasAuthorship W4229011327A5033818354 @default.
- W4229011327 hasAuthorship W4229011327A5044862124 @default.
- W4229011327 hasAuthorship W4229011327A5069095946 @default.
- W4229011327 hasBestOaLocation W42290113272 @default.
- W4229011327 hasConcept C104317684 @default.
- W4229011327 hasConcept C121608353 @default.
- W4229011327 hasConcept C1491633281 @default.
- W4229011327 hasConcept C150194340 @default.
- W4229011327 hasConcept C162317418 @default.
- W4229011327 hasConcept C2777933648 @default.
- W4229011327 hasConcept C2778265714 @default.
- W4229011327 hasConcept C2779013556 @default.
- W4229011327 hasConcept C2779723316 @default.
- W4229011327 hasConcept C2780192828 @default.
- W4229011327 hasConcept C2780932548 @default.
- W4229011327 hasConcept C28328180 @default.
- W4229011327 hasConcept C502942594 @default.
- W4229011327 hasConcept C54355233 @default.
- W4229011327 hasConcept C55427017 @default.
- W4229011327 hasConcept C555283112 @default.
- W4229011327 hasConcept C61367390 @default.
- W4229011327 hasConcept C76419328 @default.
- W4229011327 hasConcept C86339819 @default.
- W4229011327 hasConcept C86803240 @default.
- W4229011327 hasConcept C95444343 @default.